Limited good and limited vision: Multidrug-resistant tuberculosis and global health policy

Social Science and Medicine

Volumn 61, Issue 4 SPEC. ISS., 2005, Pages 847-859

  Jim, Yong Kim ^a   Shakow, Aaron ^a   Mate, Kedar ^a   Vanderwarker, Chris ^a   Gupta, Rajesh ^a   Farmer, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Health policy; Poverty; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

HEALTH POLICY; TUBERCULOSIS;

COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; POLITICS; POVERTY; REVIEW; SOCIAL ASPECT; TUBERCULOSIS;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 20444430787     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2004.08.046     Document Type: Article

References (89)

1. A. Attaran, K.I. Barnes, C. Curtis, U. d'Alessandro, C.I. Fanello, M.R. Galinski, G. Kokwaro, S. Looareesuwan, M. Makanga, T.K. Mutabingwa, A. Talisuna, J.F. Trape, and W.M. Watkins WHO, the Global Fund, and medical malpractice in malaria treatment Lancet 363 2004 237 240
2. R. Bayer, and D. Wilkinson Directly observed therapy for tuberculosis history of an idea Lancet 345 8964 1995 1545 1548
3. M.C. Becerra, J. Freeman, J. Bayona, S.S. Shin, J.Y. Kim, J.J. Furin, B. Werner, A. Sloutsky, R. Timperi, M.E. Wilson, M. Pagano, and P.E. Farmer Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis International Journal of Tuberculosis and Lung Disease 4 2 2000 108 114
4. K. Brudney, and J. Dobkin Resurgent tuberculosis in New York city human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs American Review of Respiratory Disease 144 4 1991 745 749
5. J.P. Cegielski, D.P. Chin, M.A. Espinal, T.R. Frieden, R. Rodriquez Cruz, E.A. Talbot, D.E. Weil, R. Zaleskis, and M.C. Raviglione The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century Infectious Disease Clinics of North America 16 1 2002 1 58
6. G. Codina, R. Vidal, N. Martin-Casabona, M. Miravitlles, and C. Martin Multidrug-resistant tuberculosis caused by W-related strains in three immunocompetent foreign-born patients International Journal of Tuberculosis and Lung Disease 3 1 1999 82 84
7. T. Cohen, B. Sommers, and M. Murray The effect of drug resistance on the fitness of Mycobacterium tuberculosis Lancet Infectious Disease 3 1 2003 13 21
8. R. Coker Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? International Journal of Tuberculosis and Lung Disease 6 8 2002 649 650
9. Commission on Macroeconomics and Health. (2002). Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization.
10. R. Coninx, C. Mathieu, M. Debacker, F. Mirzoev, A. Ismaelov, R. de Haller, and D.R. Meddings First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculois in prisons Lancet 353 1999 969 973
11. E. Corbett, C.J. Watt, N. Walker, D. Maher, B.G. Williams, M.C. Raviglione, and C. Dye The growing burden of tuberculosis global trends and interactions with the HIV epidemic Archives of Internal Medicine 163 2003 1009 1021
12. Durkheim, E. (1957). Professional ethics and civic morals (p. 15). London: Routledge.
13. C. Dye, S. Scheele, P. Dolin, V. Pathania, and M.C. Raviglione Global burden of tuberculosis estimated incidence, prevalence, and mortality by country JAMA 282 1999 677 686
14. D.A. Enarson The international union against tuberculosis and lung disease model national tuberculosis programme Bulletin of the International Union Against Tuberculosis and Lung Disease 76 1995 95 99
15. D.A. Enarson, H.L. Rieder, T. Arnadottir, and A. Trebucq Management of tuberculosis a guide for low income countries 2000 International Union Against Tuberculosis and Lung Disease Paris
16. M.A. Espinal, J.S. Kim, P.G. Suarez, K.M. Kam, A.G. Khomenko, G.B. Migliori, J. Baéz, A. Kochi, C. Dye, and M.C.. Raviglione Standard short-course chemotherapy for drug-resistant tuberculosis treatment outcomes in 6 countries JAMA 283 19 2000 2537 2545
17. P.E. Farmer Social scientists and the new tuberculosis Social Science & Medicine 44 3 1997 347 358
18. P. Farmer Infections and inequalities the modern plagues 1999 University of California Press Berkeley
19. P.E. Farmer Cruel and unusual drug resistant tuberculosis as punishment V. Stern R. Jones Sentenced to die? The problem of TB in prisons in East and Central Europe and Central Asia 1999 International Centre for Prison Studies London 70 88
20. P.E. Farmer TB superbugs the coming plague on all our houses Natural History 108 3 1999 46 53
21. P.E. Farmer Social medicine and the challenge of biosocial research G. Plehn Innovative structures in basic research ringberg-symposium, 4-7 October 2000 2002 Generalverwaltung der Max-Planck-Gesellschaft, Referat Presse- und Öffentlichkeitsarbeit München 55 73
22. P.E. Farmer, and J.Y. Kim Community-based approaches to the control of multidrug-resistant tuberculosis introducing "DOTS-plus" British Medical Journal 317 1998 671 674
23. P.E. Farmer, J.Y. Kim, C. Mitnick, and R. Timperi Responding to outbreaks of multidrug-resistant tuberculosis, introducing "DOTS-Plus" L.B. Reichman E.S. Hershfield Tuberculosis a comprehensive international approach 2nd ed. 1999 Marcel Dekker Inc New York 447 469
24. Farmer, P. E., Kononets, A. S., Borisov, S. E., et al. (1999b). Recrudescent tuberculosis in the Russian Federation. In: Harvard Medical School and Open Society Institute (Eds.), The global impact of drug-resistant tuberculosis (pp. 39-83). Boston: Program in Infectious Disease and Social Change, Harvard Medical School.
25. P.E. Farmer, S. Robin, S.L. Ramilus, and J.Y. Kim Tuberculosis, poverty, and "compliance" lessons from rural Haiti Seminars in Respiratory Infections 6 4 1991 254 260
26. M. Flament-Saillour, J. Robert, V. Jarlier, and J. Grosset Outcome of mutidrug resistant tuberculosis in France a nationwide case control study American Journal of Respiratory and Critical Care Medicine 160 2 1999 587 593
27. Foster, G. M. Changes in Tzintzuntzan: 1988-2000. http://hearstmuseum. berkeley.edu/exhibitions/tzin/43.html
28. G.M. Foster Peasant society and the image of limited good American Anthropologist 67 1965 293 293
29. G.M. Foster A second look at limited good Anthropological Quarterly 45 1972 57 64
30. W. Fox Compliance of patients and physicians experience and lessons from tuberculosis I British Medical Journal 287 1993 33 35
31. W. Fox, G.A. Ellaed, and D.A. Mitchison Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units. 1946-1986, with relevant subsequent publications International Journal of Tuberculosis and Lung Disease 10 Suppl 2 1999 S231 279
32. T.R. Frieden, T. Sterling, A. Pablos-Mendez, J.O. Kilburn, G.M. Cauthen, and S.W. Dooley The emergence of drug-resistant tuberculosis in New York City New England Journal of Medicine 328 8 1993 521 526
33. T. Frieden, E. Fujiwara, R. Washko, and M.A. Hamburg Tuberculosis in New York City turning the tide New England Journal of Medicine 333 4 1995 229 233
34. J.J. Furin, M.C. Becerra, S.S. Shin, J.Y. Kim, J. Bayona, and P.E. Farmer Effect of administering short-course standardized, regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains European Journal of Clinical Microbiology & Infectious Diseases 19 2 2000 132 136
35. Garrett, L. (1989). Emerging viruses, growing concerns. Newsday May 30.
36. L. Garrett The coming plague newly emerging diseases in a world out of balance 1994 Farrar, Straus, and Giroux New York
37. W.A. Geerligs, R. van Altena, W.C.M. Lange, D. van Soolingen, and T.S. van der Werf Multidrug-resistant tuberculosis long-term treatment outcome in the Netherlands International Journal of Tuberculosis and Lung Disease 4 8 2000 758 764
38. R. Gupta, J.Y. Kim, M.A. Espinal, J.M. Caudron, B. Pecoul, P.E. Farmer, and M.C. Raviglione Responding to market failures in tuberculosis control Science 293 2001 1048 1051
39. R. Gupta, M.C. Raviglione, and M.A. Espinal Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? International Journal of Tuberculosis and Lung Disease 5 12 2001 1078 1079
40. R. Gupta, J.P. Cegielski, M.A. Espinal, M. Henkens, J.Y. Kim, C.S. Lambregts-Van Weezenbeek, J.W. Lee, M.C. Raviglione, P.G. Suarez, and F. Varaine Increasing transparency in partnerships for health - introducing the green light committee Tropical Medicine and International Health 7 11 2002 970 976
41. R. Gupta, M.C. Raviglione, and M.A. Espinal Evidence and uncertainties International Journal of Tuberculosis and Lung Disease 6 8 2002 651 653
42. R. Gupta, A. Irwin, M.C. Raviglione, and J.Y. Kim Scaling up treatment for HIV/AIDS lessons learned from multidrug-resistant tuberculosis Lancet 363 2004 322 324
43. Harvard Medical School/Open Society Institute. (1999). Global impact of drug-resistant tuberculosis. Cambridge: Cambridge University Press.
44. Hippocrates, Of the Epidemics I, 1.2;
45. Airs Waters and Places IV and VII;
46. Aphorisms V, 9.
47. P.C. Hopewell, M. Sanchez-Hernandez, R.B. Baron, and B. Ganter Operational evaluation of treatment for tuberculosis results of a 'standard' 12-month regimen in Peru American Review of Respiratory Disease 129 3 1984 439 443
48. M.D. Iseman Treatment of multidrug-resistant tuberculosis New England Journal of Medicine 329 1993 784 791
49. T.A. Kenyon, S.E. Valway, W.W. Ihle, I.M. Oronato, and K.G. Castro Transmission of multidrug resistant Mycobacterium tuberculosis during a long airplane flight New England Journal of Medicine 334 15 1996 933 998
50. K. Klaudt The political causes, solutions of the current tuberculosis epidemic J. Whitman The politics of emerging and resurgent infectious diseases 2000 Macmillan Press Basingstoke
51. Kim, J., Millen, J., Irwin, A., & Gershman, J. (Eds.). (2000). Dying for growth: global inequality and the health of the poor. Monroe, Maine: Common Courage Press.
52. A. Kochi The global tuberculosis situation and the new control strategy of the World Health Organization Tubercle 72 1991 1 6
53. C.S. Lambregts van Weezenbeek, H.M. Jansen, N.J. Nagelkerke, B. van Klingeren, and J. Veen Nationwide surveillance of drug-resistant tuberculosis in the Netherlands rates, risk factors and treatment outcomes International Journal of Tuberculosis and Lung Disease 2 4 1998 296 302
54. Medical Research Council (1950). A Medical Research Council investigation: treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. British Medical Journal, 2, 1073-1085.
55. J.F. Murray Tuberculose multirésistante Rev Pneumol Clin 50 5 1994 260 267
56. L. Nader Up the anthropologist perspectives gained from studying up D. Hymes Reinventing anthropology 1972 Pantheon Books New York
57. M. Narita, P. Alonso, M. Lauzardo, E.S. Hollender, A.E. Pitchenik, and D. Ashkin Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997 Chest 120 2001 343 348
58. Nathanson, E., Gupta, R., Espinal, M. A., et al. (2004) Adverse events in the treatment of multidrug-resistant tuberculosis: preliminary results from the DOTS-Plus initiative. International Journal of Tuberculosis and Lung Disease, in press.
59. A. Pio The future of the fight against tuberculosis in the world Z Erkr Atmungsorgane 161 1 1983 96 99
60. L. Reichman Time bomb 2001 McGraw Hill New York
61. A. Rouillon The mutual assistance programme of the IUATLD. Development, contribution and significance Bulletin of the International Union Against Tuberculosis and Lung Disease 66 1991 159 172
62. A. Rubel, and L. Garro Social and cultural factors in the successful control of tuberculosis Public Health Reports 107 1992 626 636
63. F. Ryan The forgotten plague how the battle against tuberculosis was won - and lost 1993 Little, Brown Boston
64. J. Sachs Resolving the debt crisis of low income countries Brookings Papers on Economic Activity 1 2002 257 286
65. Stop TB Partnership. (2000). The economic impact of tuberculosis. Geneva: WHO.
66. Stop TB Partnership. (2001). The global plan to stop TB. Geneva: WHO.
67. P.G. Suarez, K. Floyd, J. Portocarrero, E. Alarcon, E. Rapiti, G. Ramos, C. Bonilla, I. Sabogal, I. Aranda, C. Dye, M. Raviglione, and M.A. Espinal Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients a national cohort study in Peru Lancet 359 9322 2002 1980 1989
68. A. Sweetland, J. Acha, and D. Guerra Enhancing adherence the role of group psychotherapy in the treatment of MDR-TB in urban Peru A. Cohen A. Kleinman B. Saraceno World mental health casebook 2002 Kluwer Academic/Plenum Publishers New York 51 79
69. E.E. Telzak, K. Sepkowitz, P. Alpert, S. Mannheimer, F. Medard, W. el-Sadr, S. Blum, A. Gagliardi, N. Salomon, and G. Turett Multidrug-resistant tuberculosis in patients without HIV infection New England Journal of Medicine 333 1995 907 911
70. Tuberculosis Chemotherapy Centre, Madras. (1959). A concurrent comparison of home and sanitorium treatment of pulmonary tuberculosis in South India. Bulletin of the World Health Organization, 21, 51-144.
71. United States Food & Drug Administration. (1992). The Pink Sheet, February 19.
72. United States Agency for International Development. (2002). Recent HIV seroprevalence levels by country: July 2002.
73. K. Viskum, and A. Kok-Jensen Multidrug-resistant tuberculosis in Denmark International Journal of Tuberculosis and Lung Disease 1 1997 299 301
74. World Bank. (1993). Investing in health. Washington, DC: World Bank.
75. World Health Organization. (1946). Constitution of World Health Organization. adopted and signed on 22 July 1946 by the representatives of 61 States (Official Record of World Health Organization, 2, 100).
76. World Health Organization. (1997a). Guidelines for the management of drug-resistant tuberculosis. Geneva: WHO, WHO/TB/96.210.
77. World Health Organization. (1997b). Treatment of tuberculosis: guidelines for national programmes (2nd ed.). Geneva: WHO, WHO/TB/97.227.
78. World Health Organization. (1999a). Global tuberculosis control. WHO report 1999. Geneva: WHO, WHO/TB/99.259.
79. World Health Organization. (1999b). Report on infectious diseases: removing obstacles to healthy development. Geneva: WHO.
80. World Health Organization. (2000a). Procurement of second-line anti-tuberculosis drugs for DOTS-PLUS pilot projects, Cambridge, 5-6 July 1999. Geneva: WHO, WHO/CDS/TB/2000.276
81. World Health Organization. (2000b). Tuberculosis and sustainable development: report from the ministerial conference in Amsterdam. Geneva: WHO, WHO/CDS/STB/2000.6.
82. World Health Organization. (2000c). WHO expert committee on malaria, twentieth report. WHO Technical Report Series 892. Geneva: WHO.
83. World Health Organization. (2002). Report on infectious diseases: scaling up the response to infectious disease: a way out of poverty. Geneva: WHO, WHO/CDS/2002.7.
84. World Health Organization. (2003a). Global tuberculosis control: surveillance, planning, and financing. Geneva: WHO, WHO/CDS/TB/2003.316.
85. World Health Organization. (2003b). Treatment of tuberculosis: guidelines for national programmes (3rd ed.). Geneva: WHO, WHO/CDS/STB/2003.313.
86. World Health Organization. (2003c). Model list of essential medicines (13th ed.). Geneva: WHO.
87. World Health Organization. (2004). Report of the meeting of the working group on DOTS-plus for MDR-TB. 24-25 October 2003, in press.
88. World Health Organization, International Union Against Tuberculosis and Lung Disease. (1997). Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 1994-1997. Geneva: WHO, WHO/TB/97.229.
89. World Health Organization, International Union Against Tuberculosis and Lung Disease. (2000). Anti-tuberculosis drug resistance in the world No.2, prevalence and trends. Geneva: WHO, WHO/CDS/TB/2000.278.